() saw a notable increase in short interest for the month of the April. On April 15, there were 416,900 shorted shares. This is a 13.4% increase from March 31, when the total was 367,500. The days-to-cover is currently 3.1 days based on an average trading volume 133,300 share.
Institutional Trading of Mesoblast
Recently, large investors increased or decreased their stakes. Deltec Asset Management LLC purchased a new position of shares in Mesoblast valued at $54,000 during the first quarter. Aries Wealth Management purchased a new position of shares in Mesoblast for approximately $33,000 during the first quarter. OLD Mission Capital LLC purchased a new position of shares in Mesoblast for approximately $145,000 during the fourth quarter. Jane Street Group LLC purchased a new share of Mesoblast in the 4th Quarter valued at about $187,000. Millennium Management LLC also bought shares of Mesoblast in the 4th Quarter valued at about $344,000 During Friday's trading hours, the company traded at $2.95. 242,100 shares were traded, compared with the average of 79356. Mesoblast's 12-month low is $2.14, and its 12-month high is $4.35. The company's debt-to equity ratio is 0.19. Its current ratio is 1.43, and its quick ratio is 1.43. The company's market cap is $434.89 millions, with a P/E of -4.76. It also has a beta value of 3.27. The company has a moving average of $3.26 for the last 50 days and $3.24 for the past 200 days.
The company released its last quarterly earnings report on Monday, 27th February. The company reported ($0.17) in earnings per share for the quarter. This was below analysts' expectations of ($0.15) ($0.02) Mesoblast reported a negative return of equity of 16.52 % and a net margin of 1.068.42%. The company had a revenue of $2.13m during the quarter compared to a consensus estimate of $1.50m. The sell-side analyst group predicts that Mesoblast's current fiscal year will result in a loss per share of -0.65.
Wall Street analysts forecast growth
MESO was the subject of recent analyst reports. Cantor Fitzgerald reiterated an 'overweight rating' and set a price target of $23.00 on Mesoblast shares in a report published on Wednesday, 1st February. Chardan Capital reiterated a "sell" rating and set $2.50 as the target price for Mesoblast shares in a report published on March 1. William Blair began covering Mesoblast on Thursday, 9th March in a research report. Mesoblast was covered in a report published on Thursday 16th March. They gave the company a "sell" rating. Two analysts gave the stock a sell recommendation, while one issued a "hold" rating. Three other analysts have given the company a "buy" rating. According to MarketBeat Mesoblast currently has an average rating 'Hold,' with a consensus price target of $10.13.
Mesoblast Ltd., a biopharmaceutical firm, is engaged in research, development and marketing of adult stem cells with mesenchymal ancestry. Its medicines are aimed at cardiovascular diseases, spine orthopaedic disorders, oncology, hematology, immuno-mediated and inflammatory disease.
MarketBeat.com offers a FREE daily email newsletter